Taiwan
· Delayed Price · Currency is TWD Medigen Vaccine Biologics Company Description
Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally.
The company is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection; influenza vaccine, which has completed Phase III clinical trial to treat influenza; dengue vaccine, which has completed Phase II clinical trial for the treatment of dengue fever; respiratory cell fusion virus (RSV) antibody, which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19- severe special infectious pneumonia.
Medigen Vaccine Biologics Corporation was founded in 2012 and is based in Zhubei, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.
| Country | Taiwan |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 103 |
| CEO | Leo Lee |
Contact Details
Address: No. 68, Shengyi 3rd Road Zhubei , 302 Taiwan | |
| Phone | 886 3 668 4866 |
| Website | medigenvac.com |
Stock Details
| Ticker Symbol | 6547 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006547003 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Leo Lee | Chief Executive Officer and Executive Vice President |
| Yu-Ping Yang | Chief Financial Officer |
| Shih-Shen Lee | Executive Vice President of Operations Business Unit |